Gene therapies have been incredibly successful for many rare diseases, especially diseases of the blood and immune systems. For example, patients with severe combined immunodeficiency syndrome (SCID), commonly known as bubble boy disease, can be cured after receiving a bone marrow transplant using their own cells that have been genetically altered to add back the missing gene whose absence leads to the disease. However, patients, drug companies, and governments alike must grapple with the fact that these “miracle cures” are often exorbitantly priced.
MGH researchers explain their fields of study and share their New Years resolutions in this thoughtful piece featuring Drs. Fatima Cody Stanford, Nitya Jain, Shannon Stott, Helen Riess, Sareh Parangi, Pike See Cheah, Guisy Romano-Clarke, and our very own PI, Jonathan Hoggatt. This year, the Hoggatt lab hopes to better understand hematopoietic stem cell heterogeneity to enhance bone marrow transplantation.
After several puzzling discoveries have proven that certain stem cell populations are not stem cells at all, or that some differentiated adult cells are able to revert to a stem-like state in certain situations, scientists are redefining what it means to be a stem cell. Dr. Hans Clevers, Dr. Jonathan Hoggatt, and Dr. Pamela Robey discuss tissue repair, phony treatments, and the controversy of what characterizes “stemness” in this piece by Jordana Cepelewicz of Quanta Magazine.
Hannah was awarded the prestigious American Society of Hematology “Outstanding Abstract Achievement Award” at the 2015 annual meeting as the top undergraduate abstract presenter.
Jon is currently a Contributing Editor of The Hematologist, a publication of the American Society of Hematology that updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.